Startup aims to churn out other orphan drug startups

04/25/2013 | Xconomy

Armed with $16 million in venture capital, former MedImmune boss David Mott's new enterprise Cydan will find and fund small firms with promising orphan drug candidates. Investor return will be through licensing deals with or acquisition by larger drugmakers. Mott plans to collaborate with parent and patient advocacy groups and will subcontract toxicology, pharmacology and other testing to reduce development risk.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Health Plan Administration, Payor Relations and Contracting
St. Charles Health System
Bend, OR
Compliance Sr Mgr
Amgen
Thousand Oaks, CA
Paralegal
Mylan Inc.
Washington, DC
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC